Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2022 08:00 ET | Source: IO Biotech

IO Biotech to Participate in the Jefferies London Healthcare Conference

NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
October 13, 2022 16:05 ET | Source: IO Biotech

IO Biotech Announces Appointment of New Chief Financial Officer

NEW YORK, Oct. 13, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
October 05, 2022 08:05 ET | Source: IO Biotech

IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
September 06, 2022 07:30 ET | Source: IO Biotech

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
August 11, 2022 17:00 ET | Source: IO Biotech

IO Biotech Announces Second Quarter Results for 2022

Announced initiation and dosing of first patient in global Phase 3 combination trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as first-line treatment in advanced melanomaAnnounced initiation and...
June 06, 2022 08:00 ET | Source: IO Biotech

IO Biotech to Participate in the 2022 BIO International Convention

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
May 26, 2022 17:00 ET | Source: IO Biotech

IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
May 23, 2022 08:00 ET | Source: IO Biotech

IO Biotech to Participate in the Jefferies Healthcare Conference

NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology...
May 18, 2022 07:00 ET | Source: IO Biotech

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

- First Patient Dosed in Proposed Registrational Trial in Melanoma- Multiple Sites to be Opened Across the United States, Australia, and Europe|- Trial Builds upon Phase 1 / 2 Results Recently...
May 16, 2022 16:15 ET | Source: IO Biotech

IO Biotech Announces First Quarter Results for 2022

-- Updated Data from Phase 1/2 study of IO102-IO103 in Combination with Nivolumab Showing High Response Rates in Metastatic Melanoma Presented at AACR in April -- -- Announced initiation and dosing...